Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
MAIA Stock Forecast 2026-2027
$1.35
Current Price
$81.91M
Market Cap
Buy 1
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to MAIA Price Targets
+937.0%
To High Target of $14.00
+798.9%
To Median Target of $12.14
+660.7%
To Low Target of $10.27
MAIA Price Momentum
-0.7%
1 Week Change
-7.5%
1 Month Change
-12.9%
1 Year Change
-11.8%
Year-to-Date Change
-57.7%
From 52W High of $3.19
+55.2%
From 52W Low of $0.87
📊 TOP ANALYST CALLS
Did MAIA Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if MAIA Biotechnology is one of their latest high-conviction picks.
Latest MAIA Stock Price Targets & Analyst Predictions
Based on our analysis of 1 Wall Street analyst, MAIA has a bullish consensus with a median price target of $12.14 (ranging from $10.27 to $14.00). The overall analyst rating is Strong Buy (10.0/10). Currently trading at $1.35, the median forecast implies a 798.9% upside. This outlook is supported by 1 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Robert LeBoyer at Noble Capital Markets, projecting a 937.0% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
MAIA Analyst Ratings
1
Buy
0
Hold
0
Sell
MAIA Price Target Range
Low
$10.27
Average
$12.14
High
$14.00
Current: $1.35
Latest MAIA Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for MAIA.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Feb 21, 2023 | Noble Capital Markets | Robert LeBoyer | Outperform | Initiates | $14.00 |
Maia Biotechnology Inc. (MAIA) Competitors
The following stocks are similar to MAIA Biotechnology based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
MAIA
MAIA Biotech
mkt cap
81.91M
Maia Biotechnology Inc. (MAIA) Financial Data
Valuation Metrics
Market Cap
$81.91M
Enterprise Value
$77.50M
P/E Ratio
N/A
PEG Ratio
0.5x
Price/Sales
N/A
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+10.6%
Current Ratio
1.7x
Debt/Equity
0.0x
ROE
-745.2%
ROA
-152.8%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Maia Biotechnology Inc. (MAIA) Business Model
About Maia Biotechnology Inc.
What They Do
Develops innovative cancer therapies.
Business Model
Maia Biotechnology generates revenue by developing and commercializing proprietary cancer treatments. The company focuses on harnessing the body's immune system to create novel therapies that target significant oncology indications, aiming to fill gaps in existing cancer care and improve patient outcomes.
Additional Information
Positioned in a crucial sector of the biotech industry, Maia Biotechnology addresses the rising global cancer burden with its advanced pipeline. The company's commitment to research and development emphasizes the potential for substantial impacts on the quality of life for cancer patients, making it a key player in transforming cancer treatment.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
13
CEO
Dr. Vlad Vitoc M.B.A., M.D.
Country
United States
IPO Year
2022
Website
maiabiotech.comMaia Biotechnology Inc. (MAIA) Latest News & Analysis
Latest News
Quick Summary
A $33 million common stock offering saw strong investor participation, indicating confidence in late-stage clinical progress and commercial prospects.
Why It Matters
High demand for the $33 million stock offering signals strong investor confidence, suggesting positive expectations for the company's clinical developments and future revenue potential.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
MAIA Biotechnology reported positive Phase 2 trial results for its immunotherapy in non-small cell lung cancer, showing over two years of overall survival in eight patients.
Why It Matters
The announcement of positive survival data for MAIA's immunotherapy in lung cancer enhances its market potential, potentially increasing investor interest and stock value in the $50B immunotherapy sector.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Diamond Equity Research has released an update on MAIA Biotechnology, Inc. (NYSE: MAIA), covering the company's business, recent developments, financials, and associated risks.
Why It Matters
The update from Diamond Equity Research provides crucial insights into MAIA Biotechnology's performance, valuation, and risks, influencing investor decisions and market perceptions.
Source: GlobeNewsWire
Market Sentiment:
Neutral
MAIA Biotechnology Announces Closing of $30 Million Underwritten Public Offering of Common Stock
1 month ago
Quick Summary
MAIA Biotechnology closed a public offering of 20 million shares at $1.50 each, raising $30 million. Underwriters have a 30-day option for an additional 3 million shares.
Why It Matters
MAIA Biotechnology raised $30 million through a public offering, enhancing its financial position for ongoing cancer therapies, which could influence investor confidence and stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
MAIA Biotechnology Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants
1 month ago
Quick Summary
MAIA Biotechnology has launched an underwritten public offering of common stock and pre-funded warrants. The company plans to grant underwriters a 30-day option for additional shares.
Why It Matters
MAIA Biotechnology's public offering may dilute existing shares, impacting stock value. Market conditions will influence the offering's success, affecting investor sentiment and future funding.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
A ongoing Phase 3 clinical trial for ateganosine is showing a high probability of technical success for both interim and full analysis, indicating positive prospects for the drug's approval.
Why It Matters
Successful Phase 3 results for ateganosine could lead to full approval, boosting the company's stock value and attracting investor interest in potential market opportunities.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About MAIA Stock
What is Maia Biotechnology Inc.'s (MAIA) stock forecast for 2026?
Based on our analysis of 1 Wall Street analysts, Maia Biotechnology Inc. (MAIA) has a median price target of $12.14. The highest price target is $14.00 and the lowest is $10.27.
Is MAIA stock a good investment in 2026?
According to current analyst ratings, MAIA has 1 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $1.35. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for MAIA stock?
Wall Street analysts predict MAIA stock could reach $12.14 in the next 12 months. This represents a 798.9% increase from the current price of $1.35. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Maia Biotechnology Inc.'s business model?
Maia Biotechnology generates revenue by developing and commercializing proprietary cancer treatments. The company focuses on harnessing the body's immune system to create novel therapies that target significant oncology indications, aiming to fill gaps in existing cancer care and improve patient outcomes.
What is the highest forecasted price for MAIA Maia Biotechnology Inc.?
The highest price target for MAIA is $14.00 from Robert LeBoyer at Noble Capital Markets, which represents a 937.0% increase from the current price of $1.35.
What is the lowest forecasted price for MAIA Maia Biotechnology Inc.?
The lowest price target for MAIA is $10.27 from at , which represents a 660.7% increase from the current price of $1.35.
What is the overall MAIA consensus from analysts for Maia Biotechnology Inc.?
The overall analyst consensus for MAIA is bullish. Out of 1 Wall Street analysts, 1 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $12.14.
How accurate are MAIA stock price projections?
Stock price projections, including those for Maia Biotechnology Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: April 19, 2026 6:08 PM UTC